Combining conventional therapy with immunotherapy: A risky business?
An Coosemans(KU Leuven), Ignace Vergote(KU Leuven), Louis Boon, Nicole Concin(Medical University of Vienna), Andreas du Bois(Kliniken Essen-Mitte), Sarah P. Blagden(Churchill Hospital), Mattéo Riva(KU Leuven), Jonathan A. Ledermann(London Cancer), Mansoor Raza Mirza(C4 Therapeutics (United States)), H. Ruts(KU Leuven), Thaïs Baert(Kliniken Essen-Mitte), Michel Delforge(KU Leuven), Ann Vankerckhoven(KU Leuven)
Cited by 31
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
|International Journal of Gynecological Cancer|2020|1.9k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k